3.1. Subjects and Compliance Rate
NMS
Between 10 April 2021 and 2 August 2021, 113 patients were enrolled in the trial. Of these, 55 patients were randomly assigned to the intervention group and 58 patients to the placebo group. At the conclusion of the study, the average compliance rate for all subjects was 83.19%, with no significant difference between the groups. A total of 49 (89.09%) of 55 patients in the NMS group and 45 (77.59%) of 58 in the placebo group completed the study (This study, with a sample size of 55 patients in the NMS group and 58 patients in the placebo group, has a power of 93.91% (